Post Polio is a condition that affects up to 8% of persons who survive paralytic polio; can develop as late as, 30, 40 years after the initial recovery; symptoms vary from mild weakness to severe fatigue and disability .
Fibromyalgia and diabetic neuropathy have a couple of things in common. Both conditions involve seemingly unexplainable pain, tingling, and can drastically reduce your quality of life.
Early research suggests that cannabis may have powerful therapeutic effects for both conditions, and this new pain patch offers a novel new approach for conditions that are incredibly difficult to treat.
A 2014 survey from the National Pain Foundations found that cannabis was considered the most effective pain medication by fibromyalgia patients who were willing to experiment with the herb.
Not all survey respondents had consumed cannabis. However, those that had suggested that the herb worked better at managing pain than the leading prescriptions for fibromyalgia, including Savella, Cymbalta, and Lyrica.
Small human trials of cannabis for diabetic neuropathy have also been successful. A study of 16 patients with diabetic neuropathy of the feet found the herb successfully reduced pain symptoms in a dose-dependant manner. The cannabis plant has successfully reduced nerve pain associated with conditions like multiple sclerosis as well.
While expensive cannabis-based pharmaceuticals are already available in some countries for the treatment of nervous disorders, most canna-curious patients are stuck with topical creams and oral cannabis options, which can be a little strong for the daytime.
Now, one innovative company, Cannabis Science, has released a revolutionary new topical application of cannabis medicines.
Cannabis Science designs an infused pain patch
Cannabis Science, Inc. is a pharmaceutical research company that works to develop innovative new cannabis medicines. In November of 2016, they announced their most recent project, a transdermal patch that delivers powerful pain-fighting medicine through the skin and into the bloodstream.
The company has two new patches in mind, one for fibromyalgia and one for diabetic neuropathy. While both of these patches will contain cannabinoids, each formulation and delivery method will be designed to most effectively manage symptoms of the respective illness.
In a press release announcing the new pain patch, Cannabis Science CEO Raymond Dabney explains,
The development of these two new pharmaceutical medicinal applications are just the tip of the iceberg for what we see as the future for Cannabis Science.
While we strive to increase our land capacity for growth and facilities to produce our own product to supply our scientists with proprietary materials to make these formulations, we are also busy researching more potential needs for Cannabis related medical applications and developing the methods for delivery of these medications.
Earlier in 2016, Cannabis Science began recruiting for a study on inhaled cannabis preparations for patients with asthma and lung diseases like COPD.
Cannabis Science is also not the first company to look into the transdermal applications of cannabis. Mary’s Medicinals got there first, offering cannabis-infused pain patches to medical cannabis patients in Colorado, Arizona, Nevada, Washington, Michigan, and Oregon. The company also hopes to offer their patches in California soon.
Gunilla Östlund, MSci1, Åke Wahlin, PhD2, Katharina S. Sunnerhagen, MD, PhD3,4 and Kristian Borg, MD, PhD1.
From the 1Divison of Rehabilitation Medicine, Karolinska Institutet, Department of Clinical Sciences at Danderyd Hospital, 2Department of Psychology, Stockholm University, Stockholm, 3Institute for Neuroscience and Physiology, Section for Clinical Neuroscience and Rehabilitation, Göteborg University, Göteborg, Sweden and 4Sunnaas Rehabilitation Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway.
Objective:To evaluate vitality and fatigue in post-polio pa- tients, and the relative contributions of physiological and psychological parameters to the level of vitality. Design: Multi-centre study.
Subjects: One hundred and forty-three patients with post- polio syndrome.
Methods: Inventories of background, quality of life, fatigue and sleep quality were used. Pain was evaluated using a visual analogue scale. Descriptive statistics and correlations were used for all selected parameters. Hierarchical regres- sion models were constructed to examine predictors of varia- tions in vitality, pain, reduced activity and physical fatigue.
Results:General fatigue accounted for 68% of the variation in vitality. Of this, 91% was accounted for by physiologi- cal indicators. After controlling for age, physiological para- meters accounted for 56.6% and 25%, if entered before and after the psychological parameters, respectively. The impact of the psychological parameters decreased after accounting for the physiological parameters. Physical fatigue, age and sleep quality were associated with variation in pain. Body mass index, pain and sleep quality accounted for differences in reduced activity and physical fatigue.
Conclusion: Vitality in post-polio patients depends on physio- logical parameters. Mental fatigue is not a prominent pre- dictor. Subgroups with or without fatigue, independent of age, need further study.
Key words: post-polio, fatigue, vitality, quality of life. J Rehabil Med 2008; 40: 709–714
Correspondence address: Gunilla Östlund, Department of Rehabilitation Medicine, Danderyd University Hospital, Building 39, 3rd Floor, SE-182 88 Stockholm, Sweden. E-mail: Gunilla.Ostlund@ki.se
Submitted September 21, 2007; accepted May 29, 2008
Poliomyelitis leads to muscle weakness due to destruction of the anterior horn cells. After an initial recovery there is a phase
*This article has been fully handled by one of the Associate Editors, who has made the decision for acceptance, as it originates from the institute where the Editor-in-Chief is active.
of functional stability that usually lasts from 10 to 40 years. during this phase the life circumstances of polio survivors do not differ much from the general population with respect to work and family situation (1). However, after the stable phase deterioration may occur; a condition termed post-polio syndrome (PPS) (2). The most commonly reported symptoms of PPS are increased muscle weakness, fatigue and pain in the muscles and joints. The last epidemic of polio in Sweden was in 1953 when more than 5000 people contracted poliomyelitis. Today, the prevalence of polio-affected individuals in Sweden is estimated to be 186/100,000 (3). Reported estimates of polio survivors eventually developing PPS vary from 20% to 68% (2, 4). Thus, the majority of polio survivors in Sweden are now middle-aged or older, and consequently at risk of developing PPS. Risk factors for developing PPS include time since the acute polio infection (5), age at presentation of symptoms, muscle pain at exercise, recent weight gain, joint pain (6) and female gender.
During the last decade, increasing research interest has fo- cused on fatigue in patients with PPS (7). Jubelt & Agre (8) re- ported generalized fatigue as one of the most common symptoms in PPS. Mental, as well as physical, fatigue has been reported by both Bruno et al. (9) and Schanke & Stanghelle (10).
Interestingly, and related to mental fatigue, there are con- tradicting reports regarding cognitive dysfunction in patients with PPS. Difficulties with attention, word finding, maintaining wakefulness and ability to think clearly have been reported by Bruno et al. (11). However, in most other studies cognitive function is reported to be unaffected by mental fatigue (12, 13). Furthermore, fatigued polio survivors are reported to have more mental health problems than controls or polio survivors without severe fatigue (5). In a study by Conrady et al. (14) patients, both at a post polio-clinic and in a post-polio support group, experienced significantly elevated levels of psychologi- cal distress, such as somatization and depression. Gonzalez et al. (15) reported an increase in cytokines in the cerebrospinal fluid of patients with PPS, indicating an inflammatory proc- ess.
The inflammatory processes were down-modulated by treatment with intravenous immunoglobulin followed by a clinical effect, especially on vitality, as evaluated by means of Short Form 36 (SF-36). This indicates that vitality has a central role in PPS that may be improved by means of phar- macological treatment. The subjective experience of vitality
A Neuropsychological Study of the Postpolio Syndrome: Support for Depression Without Neuropsychological Impairment
Hazendonk, Kim M. B.BSc.; Crowe, Simon F. Ph.D.
Objective: This study aimed to examine cognitive functioning in postpolio syndrome (PPS) after controlling for the effects of depression and illness behavior.
Background: Few studies have investigated the possible cognitive sequelae of PPS, despite widespread documented subjective complaints of "mental fatigue."
Method: A total of 23 PPS sufferers, 20 polio survivors without PPS, and 22 matched controls were compared using the Beck Depression Inventory-II; the Illness Behaviour Questionnaire; a chronic fatigue syndrome symptom checklist; and several measures of memory, attention, and concentration, including the Brown-Petersen Task, Stroop Test, Austin Maze, California Verbal Learning Test, Trail Making Test, Controlled Oral Word Association Test, and Symbol-Digit Modalities Test.
Results: In those participants with a medically confirmed diagnosis of PPS, there was a significantly higher level of depressive and hypochondriacal symptomatology as compared with the other two groups. Nevertheless, no significant differences existed between the three groups on neuropsychological measures.
Conclusions: These results indicate that the attention and memory difficulties reported by PPS sufferers may be linked to the physical or psychological manifestations of the illness rather than to objective decrements in cognitive performance. (NNBN 2000;13:112-118)
Neuropsiquiatría, Neuropsicología, Neurología y del Comportamiento:
Un estudio neuropsicológico del síndrome postpolio: Apoyo a la depresión sin deterioro neuropsicológico
Hazendonk, MBBSc Kim;. Crowe, Simon F. Ph D..
Objetivo: El presente estudio tuvo como objetivo examinar el funcionamiento cognitivo en el síndrome postpolio (SPP) después de controlar por los efectos de la depresión y el comportamiento de la enfermedad.
Antecedentes: Pocos estudios han investigado las posibles secuelas cognitivas del SPP, a pesar de amplia documentado quejas subjetivas de "fatiga mental".
Método: Un total de 23 enfermos de PPS, 20 supervivientes de la polio sin PPS, y 22 controles emparejados se compararon mediante el Inventario de Depresión de Beck-II, la enfermedad Cuestionario de Comportamiento, un síndrome de fatiga crónica lista de síntomas, y varias medidas de la memoria, la atención y concentración, incluyendo la tarea de Brown-Petersen, prueba de Stroop, Laberinto de Austin, California Verbal Learning Test, Trail Making Test, controlada oral Palabra Test de Asociación, y el símbolo dígitos Modalidades de prueba.
Resultados: En los participantes con un diagnóstico médico confirmado de PPS, hubo un nivel significativamente mayor de depresión y sintomatología hipocondríaca, en comparación con los otros dos grupos. Sin embargo, no existen diferencias significativas entre los tres grupos en las medidas neuropsicológicas.
Conclusiones: Estos resultados indican que las dificultades de atención y la memoria reportado por las víctimas del PPS puede estar relacionado con las manifestaciones físicas o psicológicas de la enfermedad en lugar de decrementos objetivo en el rendimiento cognitivo. (NNBN 2000, 13:112-118)